The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial

D T Arnold; C E Hooper; A Morley; P White; I D Lyburn; J Searle; M Darby; T Hall; D Hall; N M Rahman; E De Winton; A Clive; V Masani; A Dangoor; S Guglani; P Jankowska; S A Lowndes; J E Harvey; J P Braybrooke; N A Maskell

doi:10.1038/bjc.2015.77

The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial

D T Arnold, C E Hooper, A Morley, P White, I D Lyburn, J Searle, M Darby, T Hall, D Hall, N M Rahman, E De Winton, A Clive, V Masani, A Dangoor, S Guglani, P Jankowska, S A Lowndes, J E Harvey, J P Braybrooke, N A Maskell

Research output: Contribution to journal › Article (Academic Journal) › peer-review

22 Citations (Scopus)

Abstract

BACKGROUND: The effect of chemotherapy on health-related quality of life (HRQoL) in malignant pleural mesothelioma (MPM) is poorly understood. Patient-individualised prognostication and prediction of treatment response from chemotherapy is useful but little evidence exists to guide practice.

METHOD: Consecutive patients with MPM who were fit for first-line chemotherapy with pemetrexed and cisplatin\carboplatin were recruited and followed up for a minimum of 12 months. This study focussed on the HRQoL outcomes of these patients using the EQ-5D, EORTC QLQ-C30 and LC13.

RESULTS: Seventy-three patients were recruited of which 58 received chemotherapy and 15 opted for best supportive care (BSC). Compliance with HRQoL questionnaires was 98% at baseline. The chemotherapy group maintained HRQoL compared with the BSC group whose overall HRQoL fell (P=0.006) with worsening dyspnoea and pain. The impact of chemotherapy was irrespective of histological subtype although those with non-epithelioid disease had worse HRQoL at later time points (P=0.012). Additionally, those with a falling mesothelin or improvement on modified-RECIST CT at early follow-up had a better HRQoL at 16 weeks.

CONCLUSIONS: HRQoL was maintained following chemotherapy compared with a self-selected BSC group. Once chemotherapy is initiated, a falling mesothelin or improved RECIST CT findings infer a quality-of-life advantage.

Original language	English
Pages (from-to)	1183-9
Number of pages	7
Journal	British Journal of Cancer
Volume	112
Issue number	7
DOIs	https://doi.org/10.1038/bjc.2015.77
Publication status	Published - 31 Mar 2015

Research Groups and Themes

Memory
Academic Respiratory Unit

Keywords

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Carboplatin
Cisplatin
Female
Glutamates
Guanine
Humans
Lung Neoplasms
Male
Mesothelioma
Middle Aged
Palliative Care
Pemetrexed
Prospective Studies
Quality of Life
Clinical Trial
Journal Article
Multicenter Study
Observational Study

Access to Document

10.1038/bjc.2015.77

Handle.net

Persistent link

Cite this

Arnold, D. T., Hooper, C. E., Morley, A., White, P., Lyburn, I. D., Searle, J., Darby, M., Hall, T., Hall, D., Rahman, N. M., De Winton, E., Clive, A., Masani, V., Dangoor, A., Guglani, S., Jankowska, P., Lowndes, S. A., Harvey, J. E., Braybrooke, J. P., & Maskell, N. A. (2015). The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial. British Journal of Cancer, 112(7), 1183-9. https://doi.org/10.1038/bjc.2015.77

@article{5de03e9570ee481e9b4f79551ee83336,

title = "The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial",

abstract = "BACKGROUND: The effect of chemotherapy on health-related quality of life (HRQoL) in malignant pleural mesothelioma (MPM) is poorly understood. Patient-individualised prognostication and prediction of treatment response from chemotherapy is useful but little evidence exists to guide practice.METHOD: Consecutive patients with MPM who were fit for first-line chemotherapy with pemetrexed and cisplatin\carboplatin were recruited and followed up for a minimum of 12 months. This study focussed on the HRQoL outcomes of these patients using the EQ-5D, EORTC QLQ-C30 and LC13.RESULTS: Seventy-three patients were recruited of which 58 received chemotherapy and 15 opted for best supportive care (BSC). Compliance with HRQoL questionnaires was 98% at baseline. The chemotherapy group maintained HRQoL compared with the BSC group whose overall HRQoL fell (P=0.006) with worsening dyspnoea and pain. The impact of chemotherapy was irrespective of histological subtype although those with non-epithelioid disease had worse HRQoL at later time points (P=0.012). Additionally, those with a falling mesothelin or improvement on modified-RECIST CT at early follow-up had a better HRQoL at 16 weeks.CONCLUSIONS: HRQoL was maintained following chemotherapy compared with a self-selected BSC group. Once chemotherapy is initiated, a falling mesothelin or improved RECIST CT findings infer a quality-of-life advantage.",

keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Carboplatin, Cisplatin, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Mesothelioma, Middle Aged, Palliative Care, Pemetrexed, Prospective Studies, Quality of Life, Clinical Trial, Journal Article, Multicenter Study, Observational Study",

author = "Arnold, {D T} and Hooper, {C E} and A Morley and P White and Lyburn, {I D} and J Searle and M Darby and T Hall and D Hall and Rahman, {N M} and {De Winton}, E and A Clive and V Masani and A Dangoor and S Guglani and P Jankowska and Lowndes, {S A} and Harvey, {J E} and Braybrooke, {J P} and Maskell, {N A}",

year = "2015",

month = mar,

day = "31",

doi = "10.1038/bjc.2015.77",

language = "English",

volume = "112",

pages = "1183--9",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "7",

}

Arnold, DT, Hooper, CE, Morley, A, White, P, Lyburn, ID, Searle, J, Darby, M, Hall, T, Hall, D, Rahman, NM, De Winton, E, Clive, A, Masani, V, Dangoor, A, Guglani, S, Jankowska, P, Lowndes, SA, Harvey, JE, Braybrooke, JP & Maskell, NA 2015, 'The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial', British Journal of Cancer, vol. 112, no. 7, pp. 1183-9. https://doi.org/10.1038/bjc.2015.77

TY - JOUR

T1 - The effect of chemotherapy on health-related quality of life in mesothelioma

T2 - results from the SWAMP trial

AU - Arnold, D T

AU - Hooper, C E

AU - Morley, A

AU - White, P

AU - Lyburn, I D

AU - Searle, J

AU - Darby, M

AU - Hall, T

AU - Hall, D

AU - Rahman, N M

AU - De Winton, E

AU - Clive, A

AU - Masani, V

AU - Dangoor, A

AU - Guglani, S

AU - Jankowska, P

AU - Lowndes, S A

AU - Harvey, J E

AU - Braybrooke, J P

AU - Maskell, N A

PY - 2015/3/31

Y1 - 2015/3/31

N2 - BACKGROUND: The effect of chemotherapy on health-related quality of life (HRQoL) in malignant pleural mesothelioma (MPM) is poorly understood. Patient-individualised prognostication and prediction of treatment response from chemotherapy is useful but little evidence exists to guide practice.METHOD: Consecutive patients with MPM who were fit for first-line chemotherapy with pemetrexed and cisplatin\carboplatin were recruited and followed up for a minimum of 12 months. This study focussed on the HRQoL outcomes of these patients using the EQ-5D, EORTC QLQ-C30 and LC13.RESULTS: Seventy-three patients were recruited of which 58 received chemotherapy and 15 opted for best supportive care (BSC). Compliance with HRQoL questionnaires was 98% at baseline. The chemotherapy group maintained HRQoL compared with the BSC group whose overall HRQoL fell (P=0.006) with worsening dyspnoea and pain. The impact of chemotherapy was irrespective of histological subtype although those with non-epithelioid disease had worse HRQoL at later time points (P=0.012). Additionally, those with a falling mesothelin or improvement on modified-RECIST CT at early follow-up had a better HRQoL at 16 weeks.CONCLUSIONS: HRQoL was maintained following chemotherapy compared with a self-selected BSC group. Once chemotherapy is initiated, a falling mesothelin or improved RECIST CT findings infer a quality-of-life advantage.

AB - BACKGROUND: The effect of chemotherapy on health-related quality of life (HRQoL) in malignant pleural mesothelioma (MPM) is poorly understood. Patient-individualised prognostication and prediction of treatment response from chemotherapy is useful but little evidence exists to guide practice.METHOD: Consecutive patients with MPM who were fit for first-line chemotherapy with pemetrexed and cisplatin\carboplatin were recruited and followed up for a minimum of 12 months. This study focussed on the HRQoL outcomes of these patients using the EQ-5D, EORTC QLQ-C30 and LC13.RESULTS: Seventy-three patients were recruited of which 58 received chemotherapy and 15 opted for best supportive care (BSC). Compliance with HRQoL questionnaires was 98% at baseline. The chemotherapy group maintained HRQoL compared with the BSC group whose overall HRQoL fell (P=0.006) with worsening dyspnoea and pain. The impact of chemotherapy was irrespective of histological subtype although those with non-epithelioid disease had worse HRQoL at later time points (P=0.012). Additionally, those with a falling mesothelin or improvement on modified-RECIST CT at early follow-up had a better HRQoL at 16 weeks.CONCLUSIONS: HRQoL was maintained following chemotherapy compared with a self-selected BSC group. Once chemotherapy is initiated, a falling mesothelin or improved RECIST CT findings infer a quality-of-life advantage.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Biomarkers, Tumor

KW - Carboplatin

KW - Cisplatin

KW - Female

KW - Glutamates

KW - Guanine

KW - Humans

KW - Lung Neoplasms

KW - Male

KW - Mesothelioma

KW - Middle Aged

KW - Palliative Care

KW - Pemetrexed

KW - Prospective Studies

KW - Quality of Life

KW - Clinical Trial

KW - Journal Article

KW - Multicenter Study

KW - Observational Study

U2 - 10.1038/bjc.2015.77

DO - 10.1038/bjc.2015.77

M3 - Article (Academic Journal)

C2 - 25756395

SN - 0007-0920

VL - 112

SP - 1183

EP - 1189

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 7

ER -

The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial

Abstract

Research Groups and Themes

Keywords

Access to Document

Handle.net

Fingerprint

Cite this